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Abstract
Background: Endometrial cancer studies have led to a number of well-defined but mechanistically unconnected
genetic and environmental risk factors. One of the emerging modulators between environmental triggers and
genetic expression is the microbiome. We set out to inquire about the composition of the uterine microbiome and
its putative role in endometrial cancer.
Methods: We undertook a study of the microbiome in samples taken from different locations along the female
reproductive tract in patients with endometrial cancer (n = 17), patients with endometrial hyperplasia (endometrial
cancer precursor, n = 4), and patients afflicted with benign uterine conditions (n = 10). Vaginal, cervical, Fallopian,
ovarian, peritoneal, and urine samples were collected aseptically both in the operating room and the pathology
laboratory. DNA extraction was followed by amplification and high-throughput next generation sequencing (MiSeq)
of the 16S rDNA V3-V5 region to identify the microbiota present. Microbiota data were summarized using both α-
diversity to reflect species richness and evenness within bacterial populations and β-diversity to reflect the shared
diversity between bacterial populations. Statistical significance was determined through the use of multiple testing,
including the generalized mixed-effects model.
Results: The microbiome sequencing (16S rDNA V3-V5 region) revealed that the microbiomes of all organs (vagina,
cervix, Fallopian tubes, and ovaries) are significantly correlated (p < 0.001) and that there is a structural microbiome
shift in the cancer and hyperplasia cases, distinguishable from the benign cases (p = 0.01). Several taxa were found
to be significantly enriched in samples belonging to the endometrial cancer cohort: Firmicutes (Anaerostipes, ph2,
Dialister, Peptoniphilus, 1–68, Ruminococcus, and Anaerotruncus), Spirochaetes (Treponema), Actinobacteria (Atopobium),
Bacteroidetes (Bacteroides and Porphyromonas), and Proteobacteria (Arthrospira). Of particular relevance, the simultaneous
presence of Atopobium vaginae and an uncultured representative of the Porphyromonas sp. (99 % match to P. somerae)
were found to be associated with disease status, especially if combined with a high vaginal pH (>4.5).
Conclusions: Our results suggest that the detection of A. vaginae and the identified Porphyromonas sp. in the
gynecologic tract combined with a high vaginal pH is statistically associated with the presence of endometrial cancer.
Given the documented association of the identified microorganisms with other pathologies, these findings raise the
possibility of a microbiome role in the manifestation, etiology, or progression of endometrial cancer that should be
further investigated.
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Background
The causative or triggering agents for endometrial can-
cer remain elusive despite continued research along the
PI3K/PTEN/mTOR/HIF axis in type I [1] and the p53
tumor-suppressor system in type II endometrial cancer
[2]. Host genetics explain only 20 % of endometrial cancer
incidence through microsatellite instability (MSI) [3] or
abnormalities in aerobic glycolysis [4]. The efforts to
identify the cause of the remaining 80 % of cases have
led to studies of a number of environmental and host
factors including hormones [5], obesity [6], and dia-
betes [7]. However, these alone do not address the
question of tumorigenic mechanism. There is a need to
examine potential causative agents, studies of which
bring the promise of developing targeted prevention
strategies.
Here, we explore a major source of environmental influ-
ence on the uterine microenvironment—the microbiome.
Microbial influence on the etiology and progression of
cancer has already been well established for Helicobacter
pylori and gastric cancer [8]. Recent high-throughput
sequencing assays have revealed associations between
colorectal cancer and infection with Fusobacteria [9] and
Porphyromonas [10] that are suggestive of a broader
microbiome role in cancerous processes. Like the two ex-
amples above, endometrial cancer also often arises from a
pro-inflammatory profile [11]. We sought to explore the
potential microbial triggers for inflammation and tumori-
genesis through examination of the uterine microbiome in
participants with endometrial cancer.
The microbial partners along the female reproductive
tract have been long known to play an important role in
health and disease along the woman’s reproductive tract.
Lactic acid producing microbes have a strong role in de-
termining the microbial community membership of the
vaginal microbiome and have been shown to protect
against infection [12]. Gynecologic pathogens associated
with bacterial vaginosis, such as Atopobium vaginae and
Gardnerella vaginalis have been associated with obstet-
ric complications, such as preterm labor [13]. However,
few studies have directly probed the microbes within the
uterine environment and how these microbes could influ-
ence cancer within the endometrial lining. Given the in-
flammatory profile in endometrial cancer manifestation,
we hypothesized that there is a microbiome component in
the malignancy and that its signature in patients diag-




We report the results from 31 participants enrolled at the
Gynecologic Division, Mayo Clinic, Rochester, MN under
an IRB approval protocol (12–004445). The inclusion
criteria were the following: 18 years of age or older;
women undergoing hysterectomy by any standard surgical
approach; undergoing hysterectomy for benign disease,
hyperplasia, or any stage of endometrial cancer. Patients
with any of the following criteria were excluded from our
study: women who were pregnant or nursing; had taken
antibiotics within two weeks preceding surgery; surgeon
using morcellation during the hysterectomy procedure,
due to the size of the uterus or for any other reason. Upon
enrollment the participants were requested to fill out an
optional questionnaire about sexual and reproductive
health and history. The metadata from the questionnaires
was stored at REDCap [14]. Cancer participants were also
requested to provide a stool sample for the search for pu-
tative endometrial cancer signatures.
Sample collection
Vaginal and cervical samples
All participants were requested not to douche with
betadine on the day of surgery or the day immediately
preceding it. All the vaginal and cervical swabs and
scrapes were collected by the surgeon (with guidance
on site by the research team) immediately after the ad-
ministration of anesthesia and immediately preceding
the standard pre-surgical betadine douche. Both the va-
ginal and cervical swabs were performed with three
sterile Dacron swabs each and placed in a sterile tube
with 1 mL of Tris-EDTA (TE) buffer kept on dry ice
until storage at –80 °C. One of the vaginal swabs was
used for immediate on-site vaginal pH measurement
with a Hydrion measuring pH tape. The scrapes were
performed using sterilized (autoclaved at 121 °C for
20 min) pap smear spatulas and placed in sterile tubes
with TE buffer kept in dry ice until storage at –80 °C.
Uterine, Fallopian, and ovarian samples
Once removed, the uterus, Fallopian tubes, and ovaries
were handed by the surgeon to the instrumentalist
nurse who placed them inside a sterile transport bag
and into a closed sterile container. The research team
then transported the container to the pathology lab
(within the same clean area) where the organs were
handed to a pathologists’ assistant (PA) to be processed
under sterile conditions. The grossing station where the
specimen was processed was sterilized by the research
team, including all the tools needed by the PA for
handling. The PA used surgical gloves and mask when
handling the specimen. The PA performed a bilateral
cut of the uterus and splayed it. The research team ad-
vanced to the collection of the uterine swabs (Dacron)
and scrapes (sterilized pap smear spatulas) and documen-
tation (by placement of push pins in sampled locations
and digital photograph). The PA then proceeded to the
aseptic collection of samples needed for the diagnosis and,
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once complete, the research team collected the uterine,
Fallopian, and ovarian biopsies (approximately 4 mm of
tissue was collected per biopsy by the use of a pair of ster-
ile tweezers, scalpel, and surgical ruler). Each collected
sample was placed in a sterile tube with 1 mL of TE buffer
and kept on dry ice until storage at –80 °C. A petri dish
with Lysogeny broth (LB) was kept open on the grossing
station during sample collection to detect any possible air-
borne contamination of the specimen. The LB was
swabbed and the swab was stored in a tube with 1 mL of
TE and kept on dry ice until storage along with all the
other samples.
Sample processing
Once thawed, the swab and scrape samples were vor-
texed to bring the collected material into solution. The
biopsy samples were macerated by the use of sterile
pestles. The swab and scrape samples were centrifuged
for 10 min at 10,000 g to collect the bacterial cells and
the supernatant was discarded. All genomic DNA ex-
tractions were performed by using the MoBio Power-
Soil Kit (MoBio Laboratories, Inc., Carlsbad, CA, USA)
as described by the manufacturer; however, instead of
vortexing, an MP FastPrep (MP Biomedicals, Solon, OH,
USA) was used instead, for 60 s at 6.0 m/s, to obtain a
more effective and rapid lysis of the cells. After extraction
the DNA content was measured using High Sensitivity
Qubit (Life Technologies Corporation, Carlsbad, CA,
USA). The V3-V5 region of the 16S rDNA was then amp-
lified through a polymerase chain reaction (PCR) as fol-
lows: 25 μL of Kapa HiFi (Kapa Biosystems, Woburn,
MA, USA), 1.5 μL (10 uM) forward primer, 1.5 μL (10
uM) reverse primer, 50 ng of DNA with the remaining
volume being added by molecular grade water (up to a
final volume of 50 μL per reaction). The forward primer
was the universal primer 357 F (5’GTCCTACGGGAGG
CAGCAG3’) with the added construct on the 5’ end of
the 5’ Illumina Adapter (5’AATGATACGGCGACCACC
GAGATCTACAC3’) + Forward Primer Pad (5’TATGGT
AATT3’) to a total sequence: 5’AATGATACGGCGACCA
CCGAGATCTACACTATGGTAATTGTCCTACGGGAG
GCAGCAG3’ and the universal bacterial reverse primer
was 926R (5’CCGTCAATTCMTTTRAGT3’) with an
added construct on the 5’ end of the reverse complement
of 3’ Illumina adapter (5’CAAGCAGAAGACGGCATAC-
GAGATGCCGCATTCGAT3’) + Barcode (12 base pairs)
to a total sequence: 5’CAAGCAGAAGACGGCATACGA
GATGCCGCATTCGATXXXXXXXXXXXXCCGTCAAT
TCMTTTRAGT3’. The barcode introduced in the re-
verse primer construct was unique to each sample,
functioning as a genetic ID for sequencing. The PCR
cycle was the following: 95 °C for 3 min, 98 °C for 20 s,
70 °C for 15 s, 72 °C for 15 s, cycle repeated 34 times,
and 72 °C for 5 min. The products of the amplification
were verified by a TapeStation D1K Tape (2200 TapeSta-
tion Instrument, Agilent Technologies, Santa Clara, CA,
USA) to be free of contamination and to contain the ex-
pected amplification size, approximately 700 base pairs. If
the amplification was unsuccessful, the parameters of the
reaction or cycle were adjusted in repeated attempts. In
some cases (mostly biopsy samples) the amplification was
not successful even after repeated attempts. The reduced
number of microorganisms present in the upper repro-
ductive tract is likely to justify this result and attests for
the success of the sterile collection of the samples. In
samples that failed 16S rDNA amplification, NEBNext
Microbiome DNA Enrichment Kit (New England Bio-
labs Inc., Ipswitch, MA, USA) was used to separate the
microbiome from the human DNA to increase the odds
of a successful amplification from samples naturally
enriched with human DNA (mostly tissue samples).
Controls of both the DNA extraction and Microbiome
Enrichment processes were performed and are shown
in Supplement 5. Upon verification the PCR products
were purified using Agencourt AMPure (Beckman
Coulter, Brea, CA, USA). After purification the concen-
trations were measured using Qubit High Sensitivity.
The 16S rDNA sequencing was performed by the MGF
(Medical Genome facility at Mayo Clinic, Rochester)
using a high-throughput next-generation Illumina MiSeq
(San Diego, CA, USA) sequencing platform.
Sequence analysis
Sequence reads were aligned with our own custom
multiple alignment tool known as the Illinois-Mayo
Taxon Operations for RNA Dataset Organization (IM-
TORNADO) that merges paired end reads into a single
multiple alignment and obtains taxa calls [15]. IM-
TORNADO then clusters sequences into operational
taxonomic units (OTUs) using AbundantOTU+ [16].
Sequencing outcome
A total of 16,366,472 sequence reads (17,657–828,181
reads per sample) were obtained (mean of 199,591 ±
190,153 reads) after quality control. Further processing
for visualization was performed using QIIME [17] and
METAGENassist [18].
Data analysis
α-diversity and β-diversity analysis
To compare the microbiota composition between co-
horts, we summarized the data using both α-diversity
and β-diversity. α-diversity reflects species richness and
evenness within bacterial populations. Two α-diversity
metrics, the observed OTU number and the Shannon
index, were investigated. Rarefaction curves were used
to compare the α-diversity measures. The observed
OTU number reflects species richness, whereas the
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Shannon index measures both species richness and
evenness. β-diversity reflects the shared diversity between
bacterial communities in terms of ecological distance
between samples; different distance metrics provide dis-
tinctive views of community structure. Two β-diversity
measures (unweighted and weighted UniFrac distances)
were calculated using the OTU table and a phylogenetic
tree (“GUniFrac” function in the R package GUniFrac)
[19]. The unweighted UniFrac reflects differences in
community membership (i.e. the presence or absence of
an OTU), whereas the weighted UniFrac captures this
information and also differences in abundance. Rarefac-
tion was performed on the OTU table before calculating
the distances.
To assess the association with α-diversity, we fitted a
linear mixed effects model (LME) to the α-diversity met-
rics with a random intercept for each subject (“lme”
function in R package “nlme”), adjusting for covariates if
necessary. Wald test was used to assess the significance.
To assess the association with β-diversity measures, we
used a variant of PERMANOVA procedure (“adonis”
function in the R “vegan” package), which is a multivari-
ate analysis of variance based on distance matrices and
permutation [20]. To retain the within-subject correlation,
we used a block-permutation scheme, where samples from
the same participant were assigned a different subject ID.
Significance was assessed by 1000 permutations and the
covariate was adjusted if necessary. Ordination plots were
generated using non-metric multidimensional scaling
(NMDS) as implemented in R (“metaMDS” function in the
R “vegan” package).
To test for the correlation between organs, we used a
permutation test based on Bray-Curtis distance with the
test statistic calculated as the distance between the or-
gans from different participants minus the distance be-
tween the organs from the same participant. We next
permuted each participant for the same organ type using
the same block-permutation scheme as above. The p
value was calculated as the percentage of permutations
that produce a test statistic more extreme than what is
observed. To identify the taxa shared by both organs, we
used a taxon-specific Euclidean distance, defined based
on the presence and absence of a given taxon, and ap-
plied the same permutation test. To test whether the
distance from cohort 1 to cohort 2 is greater than the
distance from cohort 1 to cohort 3, we used a permuta-
tion test with the test statistic as the difference between
these two distances and block-permutation was used for
assessing the significance.
Differential abundance analysis
We conducted differential abundance analysis at phylum,
family, and genus levels and filtered rare taxa with preva-
lence less than 20 % to reduce the number of the tests.
We fit a generalized mixed-effects model to the taxa count
data using the PQL method, assuming a random intercept
for each participant to account for within-subject correl-
ation (“glmmPQL” in R “MASS” package). We fitted an
overdispersed Poisson to the counts if the zero proportion
is less than 25 % and an overdispersed Binomial model
(presence/absence) otherwise. For the overdispersed Pois-
son model, we included the log of library size as an offset
to account for variable sequencing depth. In the overdis-
persed Binomial model, the log of library size was in-
cluded as a covariate to account for potential dependence
of occurrence probability with sequencing depth. We used
the winsorized data (97 % upper quantile) to reduce the
potential impact of outliers upon the parameter estimates.
To improve power to detect differential taxa, which show
consistent change in both the uterus and lower tract
microbiome, we pooled the uterus and lower tract data
and included the sampling site (uterus/lower tract) as a
covariate in the model. The same analyses were also re-
peated for both datasets separately to confirm the source
of the identified signals using pooled data. Statistical
significance was assessed based on the Wald test. False
discovery rate (FDR) control (B-H procedure, “p.adjust” in
standard R packages) was used for correcting for multiple
testing, and FDR-adjusted p values or q values will be
reported. All statistical analyses were performed in R 3.0.2
(R Development Core Team, Vienna, Austria). The re-
ceiver operating characteristic (ROC) curve and area under
the curve (AUC) were generated using the median of the




A total of 31 Caucasian patients undergoing hysterec-
tomy were included in this study. Of those, ten women
were diagnosed with a benign gynecologic condition
(control cohort), four women were diagnosed with
endometrial hyperplasia (cancer precursor, hyperplasia
cohort), and 17 women were diagnosed with endometrial
cancer (cancer cohort). All diagnoses were made based on
the final surgical pathology following hysterectomy.
Healthy, asymptomatic women were not included in our
study because hysterectomies (surgical removal of the
uterus) are not performed on healthy individuals. The in-
clusion of this population in our study would mandate a
different collection protocol to assess the uterine environ-
ment and involve the inclusion of multiple confounding
variables that could influence the microbiome data.
Nevertheless, the inclusion of a variety of benign uterine
conditions in our control group provides an assessment of
the microbiome that is specifically associated with a can-
cerous condition and not simply the result of a diseased
state. Patients diagnosed with endometrial cancer were
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significantly older, predominantly postmenopausal, and
hypertensive (Table 1).
Microbiome characterization
In order to characterize the microbiome of the patients we
collected vaginal and cervical samples (lower genital tract)
in the operating room and endometrial, Fallopian, and
ovarian samples in the pathology laboratory (collection
details are provided in the “Methods” section). The deep-
sequencing of the V3-V5 16S rDNA region of all 238 col-
lected samples resulted in the identification of 3545
OTUs. The endometrial microbiome was dominated by
Shigella and Barnesiella, with Staphylococcus, Blautia,
and Parabacteroides particularly relevant in the benign co-
hort and Bacteroides and Faecalibacterium more relevant
in the endometrial cancer cohort (Fig. 1). The uterine
Table 1 Patient demographics
Variables Benign (n = 10) Cancer (n = 17) p value Hyperplasia (n = 4) p value vs. benign p value vs. cancer
Age (years) – Median, IQR 44.5 (42.5–52.5) 64 (58–71) 0.0001 54 (50.75–62.5) 0.0552 0.08
Caucasian ethnicity (%) 10 (100) 17 (100) 4 (100)
BMI – Median, IQR 26.6 (23.8–34.1) 32.1 (26.8–40.2) 0.07 35.4 (24–40.8) 0.29 0.89
Menopausal status 0.0034 >0.99 0.0526
Pre/Peri 8 3 3
Post 2 14 1
Gravida – Median, IQR 2 (2–3.25) 1.5 (0–4) 0.666 0 (0–2.25) 0.1 0.19
Parity – Median, IQR 2 (2–3) 1.5 (0–4) 0.569 0 (0–2.25) 0.13 0.23
History of hypertension 0.0362 0.85 0.31
Yes 1 10 1
No 8 7 3
Unknown 1 0 0
History of diabetes 0.621 >0.99 0.54
Yes 1 4 0
No 9 13 4
Smoking status 0.5911 0.46 0.75
Never smoker 5 9 3
Previous smoker 2 4 1
Current smoker 3 2 0
Unknown 0 2 0
Vaginal pH 0.0053 >0.99 0.07
Normal 6 1 2
High 4 15 2
Unknown 0 1 0
Histotype (%)
Endometrioid adenocarcinoma - 11 (64.7) -
Serous adenocarcinoma - 3 (17.6) -
Mucinous adenocarcinoma - 1 (5.9) -
Squamous adenocarcinoma - 1 (5.9) -
Carcinosarcoma - 1 (5.9) -
Grade (%)
Grade 1/Grade 2 - 13 (76.5) -
Grade 3 - 4 (23.5) -
Stage (%)
I - 13 (76.5) -
III/IV - 4 (23.5) -
BMI body mass index, IQR interquartile range
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microbiome results are consistent with the very limited
number of studies that have assessed the human micro-
biome composition through culture-based methods,
where Escherichia, Streptococcus, Staphylococcus, and En-
terococcus were found to be the predominant taxa in
women with chronic endometritis and dysfunctional
bleeding [21]. The very recent 16S rDNA assessment of
the uterine microbiome via transcervical collection is also
consistent with Bacteroides being a dominant uterine taxa
[22]. In the lower genital tract (vagina and cervix), Prevo-
tella and Lactobacillus were the dominant taxa, with Ste-
notrophomonas and Shigella more characteristic in the
benign cohort and Porphyromonas more common in the
endometrial cancer cohort (Fig. 2). These results are also
consistent with the pre-menopausal and post-menopausal
profiles reported by others [23, 24], with the exception
of Stenotrophomonas. Because our benign population is
not gynecologically healthy, but instead presented with
a variety of conditions (pelvic pain, abnormal bleeding,
fibroids, and prolapse), it is possible that Stenotropho-
monas may be more prominent in this patient population
than in an asymptomatic group of participants. Although
it is also possible that this could be the result of contamin-
ation, we did not find this taxon to be prominent in our
controls (Additional file 1). It is therefore unlikely that this
is the case. In the Fallopian tubes, Shigella and Bacteroides
were the most dominant taxa, with Staphylococcus,
Lactobacillus, Barnesiella, and Pseudomonas commonly
appearing in the benign cohort (Fig. 3). In the ovaries,
Stenotrophomas, Xanthomonas, and Lactobacillus domi-
nated the benign cohort, while Bacteroides dominated the
endometrial cancer cohort (Fig. 4). There is no current
literature on the human microbiome composition of
Fallopian tubes or ovaries.
Organ microbiome correlation
We first started by assessing if the microbiomes be-
tween the different organs were correlated. For in-
stance, whether the vaginal microbiome of a given
patient resembled the uterine microbiome of that par-
ticular patient more than the uterine microbiome of
any other patient. The results showed a very significant
correlation between all organs based on a distance-
based permutation test (See “Methods” and Table 2).
Fig. 1 Endometrial microbiome across cohorts. Only taxa present at a minimum of 5 % relative frequency in at least one participant are shown for graphical
clarity. Taxa color scheme reflects abundance relative to each patient (darker coloration represents higher abundance). Meno/Menometrorrhagia menorrhagia/
menometrorrhagia, Dysme dysmenorrhagia/pelvic pain, W/Aty with atypia, Muci mucinous, Squa squamous, Carcino carcinosarcoma, Hyper hyperplasia
Fig. 2 Vaginal/cervical (lower tract) microbiome across cohorts. Only taxa present at a minimum of 5 % relative frequency in at least one
participant are shown for graphical clarity. Taxa color scheme reflects abundance relative to each patient (darker coloration represents higher
abundance). Dysme dysmenorrhagia/pelvic pain, W/Aty with atypia, Muci mucinous, Squa squamous, Hyper hyperplasia
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The correlation was also significant, though to a lesser de-
gree, for the stool samples when compared to all organs.
The correlation structure held for both benign and cancer
cohorts (Additional file 2). Genus level analysis revealed
several genera that were significantly shared between
the lower genital tract and uterus (Additional file 3).
These results are indicative of an overall host specific
microbiome effect (host selection effect) and/or transfer
of microbiomes across the different organs (microbial
movement across organs). The correlation between organs
also suggests a potential gain in statistical power by a
combined analysis. We thus performed both combined
(uterus + lower genital tract) and separate analyses when
assessing the microbiota between different disease states.
Overall microbiome structure difference between benign,
hyperplasia, and endometrial cancer
We first compared the overall microbiota structure be-
tween disease states by investigating the α-diversity and
β-diversity. The α-diversity (number of observed OTUs
and Shannon index) in the cancer cohort was signifi-
cantly higher than in the benign cohort (p = 0.003 and
0.01 for the two α-diversity metrics, LME) and the dif-
ference was much stronger in uterus (p = 0.03 and 0.01,
Fig. 3 Fallopian tube microbiome across cohorts. Only taxa present at a minimum of 5 % relative frequency in at least one participant are shown
for graphical clarity. Taxa color scheme reflects abundance relative to each patient (darker coloration represents higher abundance). Meno/
Menometrorrhagia menorrhagia/menometrorrhagia, Dysme dysmenorrhagia/pelvic pain, W/o Aty without atypia, W/Aty with atypia, Muci
mucinous, Squa squamous, Hyper hyperplasia
Fig. 4 Ovarian microbiome across cohorts. Only taxa present at a minimum of 5 % relative frequency in at least one participant are shown for
graphical clarity. Taxa color scheme reflects abundance relative to each patient (darker coloration represents higher abundance). Dysme
dysmenorrhagia/pelvic pain, W/Aty with atypia, Squa squamous, Hyper hyperplasia
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Fig. 5) than in the lower genital tract (p = 0.17 and 0.31,
Additional file 4). The endometrial α-diversity of the
hyperplasia cohort was similar to the cancer cohort and
was also significantly higher than the benign cohort (p =
0.07 and 0.04, Fig. 5). β-diversity analysis revealed a sig-
nificant difference in the overall microbiota structure be-
tween the three cohorts (p = 0.01, unweighted UniFrac,
PERMANOVA, Fig. 6). Consistent with the α-diversity
analysis, the difference was mainly observed in the
uterus (p = 0.05 and 0.11 for uterus and lower genital
tract, unweighted UniFrac). We next conducted pairwise
comparisons using the endometrial samples. The endo-
metrial microbiome of both endometrial cancer and
hyperplasia cohorts displayed some level of difference
from the benign cohort (p = 0.09 and 0.07, unweighted
UniFrac). In contrast, the hyperplasia cohort was not
distinguishable from the endometrial cancer cohort (p =
0.23, unweighted UniFrac) (Fig. 6). Comparison of the
distance between the benign and hyperplasia cohort to the
distance between cancer and hyperplasia cohort reveals
that hyperplasia is closer to the cancer cohort (p = 0.05,
unweighted UniFrac, permutation test; Additional file
5). Interestingly, the distance between the benign and
hyperplasia cohort is also significantly larger than that be-
tween the benign and cancer cohort (p = 0.05, unweighted
UniFrac, Additional file 5). Because endometrial hyperpla-
sia can be a clinical precursor to endometrial cancer, and
the uterine microbiome of the four patients diagnosed
with endometrial hyperplasia is distinct from the benign
cohort and presents some but not complete clustering
with an endometrial cancer subgroup, we removed these
patients from the primary analysis. This allowed us to
compare the benign and endometrial cancer cohorts with-
out the impact of the hyperplasia cases. These were later
introduced in a secondary analysis.
The dataset also contains Fallopian and ovarian sam-
ples. We therefore tested the microbiota difference
between the benign and cancer cohorts for these two
organs. Interestingly, we identified a significant differ-
ence for the ovaries (p = 0.003, unweighted UniFrac,
Additional file 6) suggesting a microbiome connection
between the ovarian microniche and endometrial can-
cer presence/absence.
Endometrial cancer microbiome signature
After the overall microbiome assessment, we performed
taxa analysis to determine whether the benign and endo-
metrial cancer cohort displayed differential microbiota.
We first performed a combined analysis pooling the sam-
ples from both the uterus and lower genital tract. At the
genus level there were 12 taxa significantly enriched in the
endometrial cancer cohort (Table 3 and Additional file 7,
q < 0.10). When we further inquired at a finer level
(OTU), we found eight OTUs significantly associated with
endometrial cancer (Table 4, q < 0.05). OTU 8 (Atopobium
sp.) and OTU 9 (Porphyromonas sp.) became of particular
relevance since they were pervasive across samples recov-
ered from endometrial cancer patients and largely absent
Table 2 Organ correlation p values based on Bray-Curtis
distance-based permutation tests
Fallopian Lower Ovary Stool Uterus
Fallopian 0 0.001 0.001 0.005 0.001
Lower 0.001 0 0.001 0.014 0.001
Ovary 0.001 0.001 0 0.022 0.001
Stool 0.005 0.014 0.022 0 0.013
Uterus 0.001 0.001 0.001 0.013 0
Fig. 5 α-diversity comparison between different disease states in the endometrial microbiome. Error bars represent the standard errors. a
Observed OTU number. b Shannon index
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from the samples recovered from patients in the benign
cohort. The Atopobium V3-V5 16S rDNA signature
matches (100 %) that of Atopobium vaginae, a well-known
vaginal pathogen [25]. The Porphyromonas signature is a
close match (99 % sequence identity) to Porphyromonas
somerae (Fig. 7), a described pathogen recovered from soft
tissue and bone infections [26]. Separate analyses of
endometrial and lower genital tract samples revealed a
high concordance of the identified genera from the
pooled analysis, indicating that both uterine and lower
genital tract microbiota may be associated with cancer
diagnosis (Table 3).
Vaginal pH and endometrial cancer
Vaginal pH was significantly correlated with an endo-
metrial cancer diagnosis (p = 0.0053), with endometrial
cancer patients typically displaying a high vaginal pH
(>4.5). However, the vaginal pH is known to raise in ap-
proximately 95 % of postmenopausal women [27] due to
physiological and microbiological changes [28]. Therefore,
the correlation between endometrial cancer and high vagi-
nal pH could not be detangled from age effects alone.
Nevertheless, we were able to determine that the micro-
biome pH effects were independent of the microbiome
disease effects in the uterus since the vaginal pH level was
not significantly correlated with the uterine microbiome
(p = 0.22 and 0.29, unweighted and weighted UniFrac,
PERMANOVA), indicating that they can be used as dis-
tinct factors.
Lower tract microbiome association with endometrial
cancer
In the lower genital tract, the association of Atopobium
vaginae and the identified Porphyromonas sp. with a
diagnosis of endometrial cancer has a sensitivity of 73–
93 %, and specificity of 67–90 % (Fig. 8). The sensitivity is
improved if the vaginal pH is factored in, although specifi-
city is decreased (Table 5; sensitivity – 100 %, specificity –
60 %).
Endometrial hyperplasia microbiome
We had four patients with a final diagnosis of endometrial
hyperplasia, which is a known endometrial cancer precur-
sor, in particular in the case of complex hyperplasia with
atypia. Three of our patients had simple hyperplasia
without atypia (H07, H08, and H63) and one had complex
hyperplasia with atypia (H72). Interestingly, the Atopobium
vaginae and the Porphyromonas sp. presence/absence
Fig. 6 Ordination plot based on unweighted UniFrac distance
depicting the relationship between different disease states. Each
point represents a sample and is colored by sample group
Table 3 Significant bacterial genera between benign and endometrial cancer cohorts
Combined q < 0.10 Value Standard error Degrees of freedom t value p value q value Test
Firmicutes; Anaerostipes 3.4 0.795 25 4.3 0.0002 0.017 Presence/absence
Firmicutes; ph2 3.1 0.829 25 3.7 0.0010 0.031 Presence/absence
Spirochaetes; Treponema 3.9 1.066 25 3.7 0.0011 0.031 Presence/absence
Actinobacteria; Atopobium 2.5 0.707 25 3.5 0.0017 0.036 Presence/absence
Bacteroidetes; Bacteroides 1.1 0.332 25 3.3 0.0026 0.044 Counts
Proteobacteria; Arthrospira 3.6 1.150 25 3.1 0.0044 0.062 Presence/absence
Firmicutes; Dialister 1.2 0.405 25 3.0 0.0061 0.073 Presence/absence
Firmicutes; Peptoniphilus 1.4 0.494 25 2.9 0.0074 0.075 Presence/absence
Firmicutes; 1-68 1.3 0.465 25 2.9 0.0080 0.075 Presence/absence
Firmicutes; Ruminococcus 0.9 0.319 25 2.8 0.0109 0.082 Counts
Bacteroidetes; Porphyromonas 1.8 0.664 25 2.7 0.0111 0.082 Presence/absence
Firmicutes; Anaerotruncus 1.3 0.477 25 2.7 0.0117 0.082 Presence/absence
Significant bacterial genera between benign and endometrial cancer cohorts in the vaginal, cervical, and endometrial microbiome as determined by generalized
mixed effect model (FDR q < 0.10). All genera are enriched in the endometrial cancer cohort
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profile of the vaginal microbiome of these four patients
more closely resembled a benign microbiome signature
(Table 5), while the uterine microbiome signature of two of
them (H63 and H72) were closer to an endometrial cancer
signature.
Snapshots of progression
The correlation and variation between the microbiomes
recovered is illustrated in the snapshots, which demon-
strate the variable microbiome landscape within and be-
tween patients (Fig. 9). We were able to successfully
amplify bacterial DNA from 94 % of the lower genital
tract samples (vaginal/cervical), 87 % of uterine samples,
50 % of the Fallopian, 61 % of ovarian, 29 % of urine,
and 17 % of peritoneal or ascites samples. This progres-
sion is likely representative of the bacterial burden in the
different body sites.
Discussion
Here we present a pilot high-throughput microbiome as-
sessment of the female reproductive tract of patients di-
agnosed with a variety of benign uterine conditions
warranting a hysterectomy (abnormal bleeding, fibroids,
uterine prolapse, and pelvic pain), endometrial hyperpla-
sia (with and without atypia), and an endometrial cancer
diagnosis (endometrioid, mucinous, serous, squamous,
and carcinosarcoma). The dominant taxa in the vaginal
and cervical (lower tract) microbiome were Prevotella
and Lactobacillus, which is consistent with current vagi-
nal microbiome literature [23]. The dominant bacteria in
the uterine microbiome were Shigella and Barnesiella,
which is also consistent with the existent culture-based
literature of the uterine microbial composition in women
with endometritis and abnormal bleeding [21]. However,
in contrast with our data, these authors reported low
concordance between the vaginal and uterine bacteria.
Table 4 Significant bacterial operational taxonomic units (OTUs) between benign and endometrial cohorts
Combined q < 0.05 Value Standard error Degrees of freedom t value p value q value Test
OTU 107: Firmicutes; Anaerostipes 3.3 0.725 25 4.6 0.0001 0.014 Presence/absence
OTU 143: Firmicutes; Ruminococcus 3.1 0.738 25 4.2 0.0003 0.019 Presence/absence
OTU 8: Actinobacteria; Atopobium 2.5 0.603 25 4.1 0.0004 0.019 Presence/absence
OTU 3197: Bacteroidetes; Bacteroides 2.5 0.655 25 3.9 0.0007 0.024 Presence/absence
OTU 3213: Bacteroidetes; Bacteroides 1.7 0.499 25 3.5 0.0018 0.043 Presence/absence
OTU 9: Bacteroidetes; Porphyromonas 1.9 0.554 25 3.4 0.0021 0.043 Presence/absence
OTU 138: Bacteroidetes; Bacteroides 1.7 0.517 25 3.4 0.0024 0.043 Presence/absence
OTU 181: Firmicutes; Dialister 2.0 0.585 25 3.4 0.0025 0.043 Presence/absence
Significant bacterial OTUs between benign and endometrial cohorts in the vaginal, cervical, and endometrial microbiome as determined by mixed effect model
(FDR q < 0.05). All OTUs shown in the table are enriched (more prevalent) in the endometrial cancer cohort
Fig. 7 Maximum likelihood phylogenetic tree of the V3-V5 16S rDNA region of the recovered Porphyromonas sp. a Recovered from children with
atopic dermatitis. b Recovered from buffaloes with postpartum endometritis. c Recovered from Holstein dairy cows with postpartum metritis. Pro-
duced with FASTTREE
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Despite the low number of patients in our study (n =
31), the microbiome correlation between all organs (va-
gina/cervix, uterus, Fallopian tubes, ovaries) was very
significant, including the stool recovered from each pa-
tient. We interpret these results to indicate that there is
a strong selective host effect on the microbiome and/or
that there is movement or transfer of microorganisms
across the different body sites. Since the samples were
not collected simultaneously or in the same location or
by the same personnel, we do not believe this correl-
ation to be the result of an artifact. In addition, the
stool samples were collected by the patient and proc-
essed separately, further supporting the veracity of the
correlation. The microbiome organ correlations were
equally significant for benign and endometrial cancer
patients. Because we do not have healthy asymptomatic
patients in this study we cannot assess whether this
correlation is generally present or if it may be indicative
of a diseased status in itself. We were unable to amplify
a positive bacterial signal in about 40–50 % of all
Fallopian and ovarian tissue biopsies collected. We
conjecture that these results indicate a very low bacter-
ial load (below detection) rather than a truly sterile
environment. Further advancements in our ability to
detect and amplify bacterial DNA from tissue samples
should improve this success rate.
Our results indicate that endometrial hyperplasia can
be distinguished from a benign uterine condition based
on its microbiome structure, suggesting either a micro-
biome role in the early phases of cellular transformation
or a notorious response to physiologic or chemical
gradient shifts within the host’s cellular microenviron-
ment. This structural differentiation is not apparent be-
tween hyperplasia and endometrial cancer patients or
between benign and endometrial cancer patients. This
could be indicative of a transient microbial ecological
disturbance that is later normalized to a new equilibrium
state, overall closer to the starting point.
Our results suggest that the detection of A. vaginae
and the identified Porphyromonas sp. in the gynecologic
tract is associated with the presence of endometrial
cancer, especially if combined with a high vaginal pH
(>4.5). Though cause and effect cannot be discerned
from association alone, examination of the hyperplasia
cases shows that although these microbes are absent
from the lower tract, they are present in half the cases
in the uterus, supporting an early disease role for these
microbes. A. vaginae has been increasingly recognized
as a prominent gynecologic and obstetric pathogen, be-
ing positively associated with Nugent scores and bacter-
ial vaginosis [25], intrauterine infections [29], and other
invasive infections of the female genital tract [30].
While we did not anticipate finding Atopobium to be
associated with endometrial cancer, we provided all pa-
tients with a comprehensive questionnaire about present
and past gynecologic and obstetric diseases or conditions.
One question directly asked if the patient had a current or
past diagnosis of bacterial vaginosis. Only one patient
(H72), a patient with hyperplasia, declared having had
bacterial vaginosis in the past (more than six months away
from present time). Through verification of the medical
records, which is allowed by our institutional IRB, no
Fig. 8 ROC curve for Atopobium vaginae and Porphyromonas sp. presence in the lower reproductive tract (vagina/cervix) and disease status
(benign vs. endometrial cancer)
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additional patients had a previous diagnosis of bacterial
vaginosis in their medical record. While bacterial vagin-
osis is a condition difficult to diagnose and not always
medically reported, we believe we did all we could rea-
sonably do to assess the prevalence of this disease in
our study population. Given that only one patient indi-
cated a past occurrence of bacterial vaginosis, we do
not have evidence that this disease impacted our results
significantly or differently among our benign and study
cohort. While the specific Porphyromonas sp. has yet to
be characterized in the literature, the association of
members of the Porphyromonas genus with cancers has
been recently verified. Porphyromonas gingivalis has
been found to be an accurate biomarker for risk of
death due to orodigestive cancer, independently of peri-
odontal disease [31], and the carriage of Porphyromonas
species has also been found to be associated with colorec-
tal cancer participants [10]. Given the correlation of these
two microorganisms with the disease along with their as-
sociation with other pathologies, it is possible that they
are involved in the etiology or aggravation of conditions
leading up to the development of endometrial cancer.
Based on the documented association of A. vaginae [32]
with bacterial vaginosis, it is possible that this microbe
causes a chronic inflammatory profile that eventually leads
to local immune dysregulation and facilitates intracellular
Table 5 Correlation between the detection of Atopobium vaginae and Porphyromonas sp. and vaginal pH with disease status
Benign pH A. vaginae Porphyromonas sp. A*P A or P + pH
B02 Normal Positive Negative Negative Negative
B04 Normal Negative Negative Negative Negative
B05 Normal Negative Negative Negative Negative
B09 Normal Negative Negative Negative Negative
B24 Normal Negative Negative Negative Negative
B25 High Positive Negative Negative Positive
B26 High Negative Positive Negative Positive
B27 High Positive Positive Positive Positive
B30 Normal Negative Negative Negative Negative
B32 High Positive Negative Negative Positive
Cancer pH A. vaginae Porphyromonas sp. A*P A or P + pH
EC06 High Positive Positive Positive Positive
EC10 High Positive Positive Positive Positive
EC11 High Positive Positive Positive Positive
EC12 High Positive Positive Positive Positive
EC13 Normal Positive Positive Positive Positive
EC14 Normal Positive Positive Positive Positive
EC15 Normal Positive Positive Positive Positive
EC19 High Positive Positive Positive Positive
EC22 Normal Positive Positive Positive Positive
EC28 High Positive Positive Positive Positive
EC31 High Positive Negative Negative Positive
EC42 High Positive Negative Negative Positive
EC54 High Positive Positive Positive Positive
EC62 NA Negative Positive Negative NA
EC65 High Positive Negative Negative Positive
Hyperplasia pH A. vaginae Porphyromonas sp. A*P A or P + pH
H07 High Negative Negative Negative Negative
H08 High Negative Negative Negative Negative
H63 Normal Negative Positive Negative Negative
H72 Normal Positive Negative Negative Negative
Correlation between the vaginal/cervical detection of Atopobium vaginae and Porphyromonas sp. (positive = detected/negative = undetected) and vaginal pH
measurement (normal ≤ 4.5; high > 5) with disease status
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infection by Porphyromonas species. Porphyromonas spe-
cies have been found intracellularly [33] and it is conceiv-
able that the microorganism we found is capable of
disrupting normal cell regulatory functions that may even-
tually lead to a carcinogenic trigger. The trigger could
then be reinforced by the anoxic microenvironment
fomented by these microorganisms. We believe this to be
a hypothesis worthy of mechanistic investigation.
Our study is limited by a small sample size, due to the
technical difficulty of collecting these specimens in real
time in the operating room and in the pathology labora-
tory within a sterile field while guaranteeing that the diag-
nosis and diagnostic time is not impact by our research
procedures. While sample size is always a valid concern,
based on the microbiome-based power calculation, the
current sample size is powered to detect a relatively large
overall effect: 90 % power for an ω2 = 0.04, unweighted
UniFrac, an effect size similar to that of antibiotics [34].
Even at this small sample size, we were still able to identify
significant microbiome differences between disease states
and identify differential abundant taxa after multiple test-
ing correction. Though the increased power may be par-
tially due to the inclusion of multiple replicates for each
participant and the use of sophisticated statistical models
to address the correlation between replicates and thus re-
duce the sampling error, these significant results neverthe-
less indicate that there is a large difference between
benign and cancer states.
Fig. 9 Example collections. Only taxa present at more than 5 % relative frequency per sample are shown for graphical clarity. a Patient B02. b
Patient H72. c Patient EC19
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We investigated potential sources of confounding in this
comparative study. The study involved slightly different
methods of sampling the microbiota including variation in
bacterial DNA enrichment (used to separate bacterial
DNA from human DNA in tissue samples), collection type
(swab versus scrape versus biopsy), and sampling position
(posterior versus superior). Based on marginal PERMA-
NOVA tests, we were able to detect significant effects of
bacterial DNA enrichment method and collection type in
profiling the microbiota (p < 0.001, unweighted UniFrac)
while the sampling position was not significant (p = 0.28
and 0.67, unweighted and weighted UniFrac). However,
these technical variables were not true confounders in this
comparative study due to roughly equal proportions of
different sampling methods in both benign and cancer co-
horts (p > 0.3, Fisher’s exact test). In fact, if these technical
variables were adjusted in the model, we achieved a simi-
lar level of statistical significance in testing the microbiota
difference between the two cohorts (data not shown). We
thus ruled out the potential confounding effects of these
technical variables. Among the demographical and clinical
variables, age, BMI, vaginal pH level, menopausal status,
and history of hypertension were potential confounders,
which had different distributions in the benign and cancer
cohorts (Table 1). Marginal PERMANOVA tests on the
uterus samples revealed that these variables had less sig-
nificant effects on the endometrial microbiota than the co-
hort effect (Additional file 8), indicating that the
observed difference could not be completely explained
by these potential confounders. However, a larger sam-
ple study may be needed to disentangle these con-
founding effects with confidence. In order to
specifically address concerns that the observed findings
could be impacted by the age differential between our
benign and cancer cohorts, we performed a subset ana-
lysis where we extracted patients in the age range of
48–60 years with both a cancer and benign diagnosis.
We repeated the analysis with this age-matched subset
and we still observed the same trend for both A. vagi-
nae and Porphyromonas, though less significant due to
the reduction in the sample size (6 cancer versus 5 be-
nign, Additional file 9). Although age differential is a
direct reflection of the patient populations, enrollment
targeted efforts will be made in future studies to de-
crease this gap.
Lastly, while our enrollment exclusion and inclusion
criteria did not specify nor exclude any ethnic or racial
description, our study population is entirely Caucasian.
Although this is a representative reflection of the com-
position of our patient population at Mayo Clinic, Roch-
ester, MN, it is not representative of the country’s
demographics. In future studies we will seek an ethnic-
ally diverse patient population to investigate whether
our results extend to other populations.
Future directions
Extending this study to a larger number of patients will
allow for the verification of the findings and increase the
statistical power. Culturing the identified Porphyromonas
sp. and investigating its effects on endometrial cells and
their immunological pro-inflammatory profile response,
especially in the co-presence of A. vaginae, is warranted.
Because of the modifiable nature of the microbiome,
these findings also hold promise to endometrial cancer
prevention.
Conclusions
We found a distinct microbiome signature in patients with
endometrial cancer and hyperplasia. We have shown that
in our study population the detection of A. vaginae and
the identified Porphyromonas sp. in the gynecologic tract
is associated with the presence of endometrial cancer, es-
pecially if combined with a high vaginal pH (>4.5). These
findings provide important insights into the etiology or
manifestation of the disease with broad implications for
biomarker development in the early detection of and
screening for endometrial cancer.
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